Premium
Medicines Adaptive Pathways to Patients: Why, When, and How to Engage?
Author(s) -
Eichler HansGeorg,
Bedlington Nicola,
Boudes Mathieu,
Bouvy Jacoline C.,
Broekmans André W.,
Cerreta Francesca,
Faulkner Stuart D.,
Forda Susan R.,
Joos Angelika,
Cam Yann,
Mayer Mark H.,
Pirard Vinciane,
CorriolRohou Solange
Publication year - 2019
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1121
Subject(s) - milestone , life span , relevance (law) , product (mathematics) , process (computing) , medicine , psychology , gerontology , computer science , political science , history , mathematics , archaeology , geometry , law , operating system
Medicines Adaptive Pathways to Patients (MAPPs) seeks to foster access to novel beneficial treatments for the right patient groups at the earliest appropriate time in the product life‐span, in a sustainable fashion. We summarize the MAPPs engagement process and critical questions to be asked at each milestone of the product life‐span. These considerations are of relevance for regulatory and access pathways that strive to address the “evidence vs. access” conundrum.